Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Therapy

Statins and liver disease: from concern to 'wonder' drugs?

Nature Reviews Gastroenterology & Hepatology volume 12, pages 320–321 (2015)Cite this article

Subjects

The benefits of statins go beyond decreasing cholesterol levels; in liver disease, statins reduce the risk of progressive liver fibrosis and provide protection during infections and ischaemia–reperfusion injury. New evidence shows that statins improve response to interferon-based anti-HCV therapy, decrease progression to cirrhosis and likelihood of developing hepatocellular carcinoma.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Chang, C. H. et al. Severe hepatic injury associated with different statins in patients with chronic liver disease: a nationwide population-based cohort study. J. Gastroenterol. Hepatol. 30, 155–162 (2015).

    Article  CAS  PubMed  Google Scholar 

  2. Lewis, J. H. et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 46, 1453–1463 (2007).

    Article  CAS  PubMed  Google Scholar 

  3. Popescu, C. I. et al. Hepatitis C virus life cycle and lipid metabolism biology. Biology (Basel) 3, 892–921 (2014).

    CAS  Google Scholar 

  4. Butt, A. A. et al. Effect of addition of statins to antiviral therapy in HCV infected persons: Results from ERCHIVES. Hepatology. http://dx.doi.org/10.1002/hep.27835.

  5. Schaefer, E. A. & Chung, R. T. HCV and host lipids: an intimate connection. Semin. Liver Dis. 33, 358–368 (2013).

    Article  CAS  PubMed  Google Scholar 

  6. Zhu, Q. et al. Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C: a systematic review and meta-analysis. Antiviral Res. 98, 373–379 (2013).

    Article  CAS  PubMed  Google Scholar 

  7. Abraldes, J. G. et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 136, 1651–1658 (2009).

    Article  CAS  PubMed  Google Scholar 

  8. Marrone, G. et al. KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. Gut http://dx.doi.org/10.1136/gutjnl-2014-308338.

  9. La Mura, V. et al. Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction. Hepatology 57, 1172–1181 (2013).

    Article  CAS  PubMed  Google Scholar 

  10. Abraldes, J. G. et al. Addition of Simvastatin to standard treatment improves survival after variceal bleeding in patients with cirrhosis. A double-blind randomized trial (NCT01095185) [abstract O167]. J. Hepatol. 6 (Suppl.), S525 (2014).

    Article  Google Scholar 

Download references

Acknowledgements

The CIBERehd is supported by the Instituto de Salud Carlos III. J.B. is supported by grants from Fondo de Investigación Sanitaria (PI13/341). The authors are indebted to C. Esteva for expert secretarial support.

Author information

Authors and Affiliations

  1. Liver Unit, Hospital Clínic-IDIBAPS, University of Barcelona, and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Villarroel 170, 08036, Barcelona, Spain

    Jaume Bosch & Xavier Forns

Authors
  1. Jaume Bosch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xavier Forns
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jaume Bosch.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bosch, J., Forns, X. Statins and liver disease: from concern to 'wonder' drugs?. Nat Rev Gastroenterol Hepatol 12, 320–321 (2015). https://doi.org/10.1038/nrgastro.2015.78

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2015.78

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing